UBV
VIRX

United Bank (Virginia)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

United Bank (Virginia)’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,200
Closed -$25.7K – 154
2024
Q1 		$25.7K Hold
25,200
– – ﹤0.01% 145
2023
Q4 		$14.4K Buy
25,200
+5,200
+26% +$3.19K ﹤0.01% 147
2023
Q3 		$20.8K Buy
20,000
+9,795
+96% +$13.3K ﹤0.01% 144
2023
Q2 		$14.4K Hold
10,205
– – ﹤0.01% 154
2023
Q1 		$16.2K Hold
10,205
– – ﹤0.01% 158
2022
Q4 		$14.9K Buy
+10,205
New +$29.8K ﹤0.01% 156

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

United Bank (Virginia)'s VIRX Position: Q2 2024 in Review

United Bank (Virginia) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2024, closing a stake of 25,200 shares — an estimated $25.7K sold.

United Bank (Virginia) first reported a position in VIRX in Q4 2022 and held it in 6 quarters. The position peaked at $25.7K in Q1 2024. 40 funds tracked by Wall St. Rank hold VIRX as of Q2 2024.

  • United Bank (Virginia) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • United Bank (Virginia) sold 25,200 Viracta Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $25.7K.
  • United Bank (Virginia) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
  • United Bank (Virginia)'s Viracta Therapeutics, Inc. Common Stock position peaked at $25.7K in Q1 2024.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2024.

Based on United Bank (Virginia)'s 13F filing for Q2 2024, filed 14 Aug 2024.